Nanologica AB (publ) has taken out a loan of MSEK 20 from the credit facility agreed in January with Flerie Invest AB.
The loan is taken out to cover the company’s temporary financial needs pending expected cash flows from the operations in preparative chromatography. After this loan, the credit facility has been used in full.
Parts of the proceeds will be used to repay a loan from a private financier of MSEK 10 that expires on July 1, 2022 and was raised in 2019 to finance investments in equipment needed to scale up production.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit www.nanologica.com.